Who are candesartan cilexetil + chlorthalidone + amlodipine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olmesartan, hydrochlorothiazide, amlodipine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/candesartan-cilexetil-chlorthalidone-amlodipine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

candesartan cilexetil + chlorthalidone + amlodipine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

candesartan cilexetil + chlorthalidone + amlodipine (candesartan cilexetil + chlorthalidone + amlodipine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker). Area: Cardiovascular.

phase 3 Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker) Angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter (NCC), L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

candesartan cilexetil + chlorthalidone + amlodipine (candesartan cilexetil + chlorthalidone + amlodipine) — Hospital Israelita Albert Einstein. This triple-combination antihypertensive reduces blood pressure through angiotensin II receptor blockade, thiazide diuresis, and calcium channel inhibition.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
candesartan cilexetil + chlorthalidone + amlodipine TARGET	candesartan cilexetil + chlorthalidone + amlodipine	Hospital Israelita Albert Einstein	phase 3	Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker)	Angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter (NCC), L-type calcium channel
olmesartan, hydrochlorothiazide, amlodipine	olmesartan, hydrochlorothiazide, amlodipine	The Louis & Rachel Rudin Foundation	marketed	Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker)	Angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter (NCC), L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker) class)

Hospital Israelita Albert Einstein · 1 drug in this class
The Louis & Rachel Rudin Foundation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). candesartan cilexetil + chlorthalidone + amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/candesartan-cilexetil-chlorthalidone-amlodipine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab